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anBACKGROUND The subcutaneous implantable cardioverter-deﬁbrillator (S-ICD) was developed to deﬁbrillate ven-
tricular arrhythmias, avoiding drawbacks of transvenous leads. The global EFFORTLESS S-ICD (Evaluation oF FactORs
ImpacTing CLinical Outcome and Cost EffectiveneSS of the S-ICD) registry is collecting outcomes in 985 patients during a
5-year follow-up.
OBJECTIVES The primary goal of the EFFORTLESS registry is to determine the safety of the S-ICD by evaluating
complications and inappropriate shock rate.
METHODS This is the ﬁrst report on the full patient cohort and study endpoints with follow-up $1 year. The predeﬁned
endpoints are 30- and 360-day complications, and shocks for atrial ﬁbrillation or supraventricular tachycardia.
RESULTS Patients were followed for 3.1  1.5 years and 82 completed the study protocol 5-year visit. Average age was
48 years, 28% were women, ejection fraction was 43  18%, and 65% had a primary prevention indication. The S-ICD
system and procedure complication rate was 4.1% at 30 days and 8.4% at 360 days. The 1-year complication rate
trended toward improvement from the ﬁrst to last quartile of enrollment (11.3% [quartile 1]) to 7.8% [quartile 2], 6.6%
[quartile 3], and 7.4% [quartile 4]; quartile 1 vs. quartiles 2 to 4; p ¼ 0.06). Few device extractions occurred due to need
for antitachycardia (n ¼ 5), or biventricular (n¼ 4) or bradycardia pacing (n ¼ 1). Inappropriate shocks occurred in 8.1% at
1 year and 11.7% after 3.1 years. At implant, 99.5% of patients had a successful conversion of induced ventricular
tachycardia or ventricular ﬁbrillation. The 1- and 5-year rates of appropriate shock were 5.8% and 13.5%, respectively.
Conversion success for discrete spontaneous episodes was 97.4% overall.
CONCLUSIONS This registry demonstrates that the S-ICD fulﬁlls predeﬁned endpoints for safety and efﬁcacy. Midterm
performance rates on complications, inappropriate shocks, and conversion efﬁcacy were comparable to rates observed
in transvenous implantable cardioverter-deﬁbrillator studies. (Evaluation oF Factors ImpacTing CLinical Outcome and
Cost EffectiveneSS of the S-ICD [The EFFORTLESS S-ICD Registry]; NCT01085435) (J Am Coll Cardiol 2017;70:830–41)
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831AB BR E V I A T I O N S
AND ACRONYM S
AF = atrial ﬁbrillation
ATP = antitachycardia pacing
CI = conﬁdence interval
HR = hazard ratio
ICD = implantable
cardioverter-deﬁbrillator
IDE = investigational device
exemption
MVT = monomorphic
ventricular tachycardia
PVT = polymorphic ventricular
tachycardia
S-ICD = subcutaneous
implantable cardioverter-
deﬁbrillator
SVT = supraventricular
tachycardia
TV-ICD = transvenous
implantable cardioverter-
deﬁbrillatorT he subcutaneous implantable cardioverter-deﬁbrillator (S-ICD) was developed with thegoal of providing a deﬁbrillator system with
no leads in or on the heart, thereby eliminating several
important complications associated with transvenous
leads, while maintaining reliable detection and deﬁ-
brillation of life-threatening arrhythmias (1).
Following the ﬁrst human feasibility trials in 2002,
S-ICD regulatory approval clinical trials began in
2008 and the S-ICD received the CE (Conformité
Européene) mark in Europe in 2009 (2). Over the past
7 years, short-term follow-up data have been reported
from the investigational device exemption (IDE) trial
and an interim subset of less than one-half of the
EFFORTLESS S-ICD (Evaluation oF Factors ImpacTing
CLinical Outcome and Cost EffectiveneSS of the S-ICD)
registry (3–5). These EFFORTLESS and IDE study
patients were pooled for analysis of 889 patients
(308 in the IDE trial, 568 in the EFFORTLESS registry,
and 13 in both studies) followed for an average of 1.8
years and 1,571 patient-years (5).SEE PAGE 842 VF = ventricular ﬁbrillation
ventricular tachycardia
This paper provides the ﬁrst report of the full
EFFORTLESS cohort, which is the largest S-ICD
database in the world with the longest follow-up so
far. This includes nearly 1,000 patients followed for
an average of 3.1 years (3,053 patient-years), enabling
a comprehensive analysis of current important issues
related to S-ICD performance. The primary goal of the
EFFORTLESS registry is to demonstrate the safety of
the S-ICD by evaluating complications and inappro-
priate shock rate (6). In addition, the following
important outcomes for device performance and
appropriate therapy were analyzed: 1) burden and
predictors of monomorphic ventricular tachycardia
(MVT); 2) incidence of recurrent MVT and impact of
lack of availability of antitachycardia pacing (ATP); 3)
differences in performance of the S-ICD in converting
induced versus spontaneous episodes; and 4) reasons
for device explant.
METHODS
The EFFORTLESS S-ICD registry is an observational,
nonrandomized, standard-of-care registry enrolling
up to 1,000 patients at 42 clinical centers in 10Dr. Hood has owned equity in Boston Scientiﬁc. Dr. Kuschyk has served as a c
Mr. Husby, and Dr. Stein are employees of Boston Scientiﬁc. Dr. Lambiase h
Boston Scientiﬁc, Medtronic, St. Jude Medical, and University College Londo
Research. All other authors have reported that they have no relationships re
Manuscript received March 30, 2017; revised manuscript received June 8, 20countries. Details of the study design and
endpoints were reported previously (6).
Brieﬂy, the objective of the EFFORTLESS
registry is to demonstrate the early as well as
mid- and long-term clinical outcomes of
the S-ICD system (Cameron Health/Boston
Scientiﬁc Inc., Minneapolis–St. Paul,
Minnesota).
Patients eligible for implantation of an
S-ICD system or with an S-ICD currently
implanted at enrollment were eligible for in-
clusion. Exclusion criteria involved patients
with spontaneous, incessant, or frequently
recurring ventricular tachycardia (VT)
amenable to ATP; patients with an indication
for cardiac resynchronization therapy or
symptomatic bradycardia, and patients with
unipolar pacemakers or implanted systems
that revert to unipolar pacing.
STUDY METHODS. Pre-speciﬁed endpoints
were perioperative (30 days post-implantation)
S-ICD complication rate, 360-day S-ICD compli-
cation rate, and the percentage of inappropriate
shocks for atrial ﬁbrillation (AF) or supraventricular
tachycardia (SVT). The registry was conducted in accor-
dance with the Declaration of Helsinki, ISO 14155:2009,
and all applicable local and national regulations, and
registered on ClinicalTrials.gov (NCT01085435). Patients
were considered enrolled after providing written
informed consent, in accordance with applicable local
and national guidelines or ethics committee or internal
review board requirements.
From August 2009 through December 2014, the
registry enrolled 994 patients. Data were collected
through the ﬁnal 1-year follow-up visit for the last
patient enrolled, which occurred in January 2016,
thereby providing a minimum follow-up of 1 year
in all eligible subjects who did not withdraw
before 1 year. The database was locked in January
2016, following completion of data monitoring
and resolution of data entry queries. The study
protocol allowed for prospective and retrospective
enrollments.
The study protocol did not require deﬁbrillation
threshold testing, but simply collected conversion
testing data. Evaluable conversion tests were those
VT =onsultant for Boston Scientiﬁc. Mr. Jones, Ms. Duffy,
as received speaker fees and research support from
n Hospitals Biomedicine National Institute of Health
levant to the contents of this paper to disclose.
17, accepted June 15, 2017.
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832with induction of sustained VT or ventricular ﬁbril-
lation (VF) that was treated by the S-ICD system.
Appropriate and inappropriate spontaneous episodes
were adjudicated and reported in the database by the
individual investigating sites. Sites reported the pre-
and post-shock rhythm for each therapy as MVT,
polymorphic ventricular tachycardia (PVT), VF, sinus
tachycardia, AF or ﬂutter, or normal sinus rhythm, as
well as indicating whether the rhythm was sustained
or nonsustained, and if the ventricular rate was
greater than the lowest programmed zone and con-
ditional zone. In addition, a sponsor review was done
to conﬁrm the rhythm, and considered sustained
shock episodes for MVT, PVT, or VF to be appropriate
if the ventricular rate was above the programmed rate
zone. In case of discordance, independent reviewers
reclassiﬁed the episodes.
All adverse events were classiﬁed by the sponsor
according to the cause of the event and resolution.
Complications were deﬁned as adverse events that
resulted in invasive intervention. The EFFORTLESS
registry protocol uses the same deﬁnition of compli-
cation types as the S-ICD IDE study does: type I,
caused by the S-ICD system; type II, caused by the
S-ICD system’s user manual or labeling of the S-ICD
system; type III, not caused by the S-ICD system, but
would not have occurred in its absence (3).
The primary safety endpoint was predeﬁned as the
subset of complications caused by the S-ICD (type I),
referred to as S-ICD complications. Additionally, all
S-ICD system- and procedure-related complications
(types I to III) were classiﬁed to quantify the safety of
the device functionality, as well as of the S-ICD sys-
tem and the implantation procedure, and are referred
to simply as complications or overall complications.
All device check follow-ups for at least 360 days
post-implantation date were recorded. Data collec-
tion from 360 days continued at least once annually
to 60 months, with required reporting of clinical
events occurring between annual follow-ups. The
expected ﬁnal follow-up date is December 2019.
During the course of the study, a ﬁeld advisory
was issued for a subset of model 1010 devices with
premature battery depletion due to a battery
manufacturing issue. There were no deaths reported
because of this battery advisory. Device changes
continued to be performed based on the regular
elective replacement indicator.
STATISTICAL ANALYSIS. Descriptive statistics are
reported usingmean SD for continuous variables and
frequency and percentage for categorical variables.
Kaplan-Meier analyses were used to estimate the
time to ﬁrst event for complications, inappropriatetherapy, and appropriate therapy. Multivariate ana-
lyses using the Cox proportional hazards model were
performed separately for the outcomes of appropriate
therapy, therapy for PVT or VF, therapy for MVT,
therapy for multiple MVT episodes, and inappropriate
therapy. Univariate analysis for each model was
performed for inclusion in multivariate modeling.
Variables with p < 0.10 in univariate analyses were
candidates for the multivariate model. Backward
selection with a p # 0.05 stay criterion was used to
determine the ﬁnal multivariate model. Subjects who
did not experience an event and remain active in the
study were censored at the date of the data snapshot
for all time-to-event analyses. All statistical analyses
were performed using SAS version 9.4 (SAS Institute,
Cary, North Carolina).
RESULTS
Of 994 patients enrolled, 6 were withdrawn before
the implantation procedure, 3 retrospective enroll-
ments were withdrawn before data entry due to in-
clusion deviation (1 participating in another study
and 2 with investigational software from the CE mark
approval trial). The remaining 985 patients were
included in the analysis. The ﬁrst-generation model
1010 S-ICD was implanted in all 985 patients. All pa-
tients were followed through the 1-year post-
implantation visit (average 3.1  1.5 years), and 928
patients remained in follow-up beyond 1 year
(Figure 1).
All patient baseline demographics are shown in
Table 1. Thirty-two percent had ischemic heart dis-
ease as an etiology, 19% had a nonischemic cardio-
myopathy, 11% had hypertrophic cardiomyopathy,
20% had a channelopathy, and the remaining 19% of
patients had a variety of other, less common etiol-
ogies. Statistical analysis neither revealed differences
between retrospectively and prospectively enrolled
patients regarding study endpoints nor differences in
complications or therapies.
IMPLANTATION PROCEDURE DETAILS. Procedure
time, deﬁned as skin-to-skin time, averaged 66.8 
28.0 min. The mean procedure time decreased from
73.1  31.9 min for successive implants 1 to 16/site, to
60.3  21.8 min (p < 0.001), for implant number above
the median of 16 implants/site.
Anesthesia use varied, with 60.4% of patients
having the S-ICD implanted under general anesthesia,
33.6% having conscious sedation, and 6.0% receiving
only local anesthesia. Either on the day of implanta-
tion or before discharge, 93.8% underwent a deﬁ-
brillation test. The median hospitalization, from
admission to discharge, was 1 day when S-ICD
FIGURE 1 Patient Flow
Enrolled Prospective
N = 501
Enrolled Retrospective
N = 493
Withdrawn
N = 4
Deaths
1
Withdrawn
7
Follow-up <30 days
0
Deaths
12
Withdrawn
37
Follow-up <1 year
0
Deaths
15
Withdrawn
23
Follow-up <2 years
193
Deaths
9
Withdrawn
16
Follow-up <3 years
174
Deaths
6
Withdrawn
5
Follow-up <4 years
187
Deaths
5
Withdrawn
6
Follow-up <5 years
207
Intents
N = 5
Implanted
N = 985
Remaining in Follow-up at 30 days
N = 977
Remaining in Follow-up at 1 year
N = 928
Remaining in Follow-up at 2 years
N = 697
Remaining in Follow-up at 3 years
N = 498
Remaining in Follow-up at 4 years
N = 300
Completed 5 year Follow-up
N  =  82
Patient ﬂow chart for the EFFORTLESS (Evaluation oF FactORs ImpacTing CLinical Outcome and Cost EffectiveneSS of the S-ICD) study
showing the number of patients enrolled, receiving an implant, and remaining in follow-up at 30 days and at each annual follow-up through
5 years. The number of patients exiting the study for death or withdrawal at each interval is shown to the right, as well as the number of
patients remaining in the study within the respective follow-up interval.
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833implantation was the sole reason for admission, and
14 days when hospitalized for other reasons, of which
2 days were from implantation to discharge.
COMPLICATIONS. For the primary pre-speciﬁed
safety endpoint, the 30- and 360-day S-ICD compli-
cation rates were 0.3% (95% conﬁdence interval [CI]:
0% to 0.6%) and 2.0% (95% CI: 1.3% to 3.1%),
respectively. The most common S-ICD complications
were cardiac oversensing, leading to inappropriateshocks (11 patients, 1.1%) and discomfort (n ¼ 8,
0.8%). Complications related to product performance
occurred due to premature battery depletion (n ¼ 5),
inability to communicate with the device (n ¼ 3), or
programmer error code (n ¼ 1), with no reports of lead
failure.
The overall complication rate was 4.1% at 30 days
and 8.4% at 360 days (Figure 2A). All S-ICD system- or
procedure-related complications are shown in
Table 2. A total of 115 (11.7%) patients experienced a
TABLE 1 Baseline Demographic Data
Overall
(N ¼ 985)
Retrospective
(n ¼ 489)
Prospective
(n ¼ 496) p Value
Age at implantation, yrs 48  17 45  17 51  16 <0.001
Male 709 (72.0) 338 (69.1) 371 (74.8) 0.05
BMI, kg/m2 27  6 27  5 28  6 0.06
Ejection fraction, % 43  18 46  18 41  19 <0.001
QRS duration, ms 106  25 104  22 107  27 0.07
Primary prevention 638 (64.9) 307 (62.9) 331 (66.9) 0.19
Ejection fraction #35% 301 (57.7) 123 (50.4) 178 (64.0) 0.002
Ischemic 221 (34.6) 87 (28.3) 134 (40.5) 0.001
Secondary prevention 345 (35.1) 181 (37.1) 164 (33.1) 0.19
Ischemic 90 (26.1) 41 (22.7) 49 (29.9) 0.13
Comorbidities
Hypertension 279 (28.3) 121 (24.7) 158 (31.9) 0.01
MI 277 (28.1) 117 (23.9) 160 (32.3) 0.004
Cardiac arrest 275 (27.9) 144 (29.4) 131 (26.4) 0.29
Congestive heart failure 261 (26.5) 95 (19.4) 166 (33.5) <0.001
Syncope 186 (18.9) 99 (20.2) 87 (17.5) 0.28
AF 157 (15.9) 61 (12.5) 96 (19.4) 0.003
Valve disease 120 (12.2) 72 (14.7) 48 (9.7) 0.02
Diabetes 111 (11.3) 42 (8.6) 69 (13.9) 0.008
Kidney disease 81 (8.2) 36 (7.4) 45 (9.1) 0.33
Stroke (including TIA) 51 (5.2) 21 (4.3) 30 (6.0) 0.21
COPD 49 (5.0) 18 (3.7) 31 (6.3) 0.06
Cardiac surgery
Previous transvenous ICD 138 (14.0) 80 (16.4) 58 (11.7) 0.03
CABG 78 (7.9) 33 (6.7) 45 (9.1) 0.18
Valve surgery 62 (6.3) 30 (6.1) 32 (6.5) 0.84
Pacemaker implant 30 (3.0) 11 (2.2) 19 (3.8) 0.15
Primary cardiac disease
Previous MI/ischemia/CAD 282 (28.6) 120 (24.5) 162 (32.7) 0.005
Channelopathy* 199 (20.2) 122 (24.9) 77 (15.5) <0.001
Hypertrophic
cardiomyopathy
106 (10.8) 50 (10.2) 56 (11.3) 0.59
Nonischemic
cardiomyopathy
91 (9.2) 32 (6.5) 59 (11.9) 0.004
Dilated cardiomyopathy 84 (8.5) 53 (10.8) 31 (6.3) 0.01
Arrhythmogenic right
ventricular dysplasia
32 (3.2) 13 (2.7) 19 (3.8) 0.30
Genetic 31 (3.1) 19 (3.9) 12 (2.4) 0.19
Valvular disease 21 (2.1) 15 (3.1) 6 (1.2) 0.04
Structural defect 19 (1.9) 13 (2.7) 6 (1.2) 0.10
Other† 44 (4.5) 22 (4.5) 22 (4.4) 0.96
Unknown 76 (7.7) 30 (6.1) 46 (9.3) 0.06
Values are mean  SD or n (%). *Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, long
QT syndrome, short QT syndrome, idiopathic ventricular ﬁbrillation, torsades de pointes. †Includes variables
with <1%: syncope of unknown origin, congestive heart failure, ventricular arrhythmia, myocarditis, cardiac
sarcoidosis.
AF ¼ atrial ﬁbrillation; BMI ¼ body mass index; CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery
disease; COPD ¼ chronic obstructive pulmonary disease; ICD ¼ implantable cardioverter-deﬁbrillator;
MI ¼ myocardial infarction; TIA ¼ transient ischemic attack.
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834complication over the average 3.1-year follow-up.
Infections requiring device removal occurred in 24
(2.4%) patients over the 3.1-year average follow-up.
By Kaplan-Meier analysis, infections requiring
device removal were most common in the ﬁrst year
(Figure 2B). There have been no reports of endo-
carditis to date. From the ﬁrst to the last quartile ofimplants over time, the 1-year complication rate
improved from 11.3% to 7.8% in quartile 2, to 6.6% in
quartile 3 and 7.4% in quartile 4 (test for trend
p ¼ 0.12 for quartile 1 vs. p ¼ 0.06 for quartiles 2 to 4).
Complications by demographic subgroups were
assessed in univariate analysis (Figure 3). On multi-
variate analysis, nonischemic heart disease was
associated with a higher rate of complications
compared with ischemic heart disease (hazard ratio
[HR]: 1.91; 95% CI: 1.17 to 3.10), as well as previous
deﬁbrillator (HR: 1.68; 95% CI: 1.03 to 2.75), QRS
width/10-ms increase (HR: 1.11; 95% CI: 1.04 to 1.19),
and body mass index per unit increase (HR: 1.03; 95%
CI: 1.00 to 1.06).
Over the 3.1-year time course, the S-ICD was
removed for a change in indication in 13 (1.3%) pa-
tients. This included a requirement for ATP in 5
(0.5%) patients, resynchronization therapy in 4
(0.4%) patients, and bradycardia pacing in 1 (0.1%)
patient. In 2 patients, the device was removed
because the indication for the implantable
cardioverter-deﬁbrillator (ICD) no longer existed due
to improved left ventricular function. One patient
required VT therapy for a VT rate <170 beats/min,
which is below the detection or therapy limit for the
S-ICD system.
INAPPROPRIATE SHOCKS. The other primary
endpoint for the EFFORTLESS registry was the inap-
propriate shock rate for AF or SVT in the ﬁrst year,
which occurred in 15 (1.5%) patients. Over the 3.1-year
average follow-up, 23 (2.3%) patients received a shock
for AF or SVT, 3 (0.3%) patients for SVT discrimina-
tion errors. In total, 8.1% of patients received an
inappropriate shock in the ﬁrst year, and 11.7%
received 1 over the average 3.1-year follow-up. Sev-
enty-six (7.7%) patients received a shock for cardiac
oversensing, mainly due to T-wave oversensing or
low-amplitude signals (63%). Twenty-two (2.2%) pa-
tients received a shock for noncardiac oversensing,
mainly electromagnetic interference.
At implantation, 850 (86%) patients had S-ICDs
programmed to dual-zone detection. By programmed
setting at implantation, the rate of inappropriate
shocks in the ﬁrst year was 7.5% for dual-zone and
11.8% for single-zone settings (p ¼ 0.08), and 11.4%
for dual-zone and 13.5% for single-zone settings at
implantation (p ¼ 0.36) over 3 years.
Univariate predictors of inappropriate therapy
appear in Online Table 1. In multivariate analysis, a
higher likelihood of receiving an inappropriate shock
was found for subjects with a pacemaker (HR: 2.74;
95% CI: 1.29 to 5.82), prior coronary artery bypass
graft (HR: 2.57; 95% CI: 1.34 to 4.89), and for each
FIGURE 2 Complication Rate
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83510-ms increment in QRS width (HR: 1.11; 95% CI: 1.04
to 1.19). Patients with a prior myocardial infarction
had a lower risk of inappropriate shocks (HR: 0.44;
95% CI: 0.26 to 0.75).
DEFIBRILLATION EFFICACY OF THE S-ICD SYSTEM.
The large EFFORTLESS database also provides more
data on the efﬁcacy of the S-ICD over time, during
both induced and spontaneous arrhythmias.
ACUTE CONVERSION TEST RESULTS. Table 3 sum-
marizes acute conversion testing results. In the ﬁrst
30 days post-implantation, 861 patients had at least 1
evaluable acute conversion test, with 857 (99.5%)
patients showing at least 1 successful conversion test
at #65 J (91.6%), 70 to 80 J (4.4%), or unrecorded
energy (3.5%). Of 17 patients requiring repositioning
of either the generator (n ¼ 6) or the electrode
(n ¼ 5) or both generator and electrode (n ¼ 6), a
successful conversion test was achieved in 15
patients.
Of the 2 subjects with repositioning who did not
have successful conversion testing in the acute
timeframe, 1 had a successful test beyond 30 days,
whereas 1 had an additional attempted conversion
test, but was unable to induce VF. Both S-ICDs
remained implanted. Two additional subjects failed
acute conversion testing, for which the device was
removed without repositioning. In total, 51 patients
had conversion testing beyond 30 days after implan-
tation (15 did not have acute testing whereas 36 had
acute testing), of which 49 were successful. The 2
subjects with failed conversions had transvenous
ICDs (TV-ICDs) implanted. Only 4 of 876 (0.45%)
cases of acute and chronic testing failed, resulting in
device removal.
APPROPRIATE THERAPY. A total of 104 patients
(10.6%; annual incidence 3.4%) had 278 appropriately
treated VT or VF episodes, including 86 storm epi-
sodes. Another 149 VT or VF episodes in 79 (8.0%)
patients met detection criteria, but self-terminated
during device charge. There were 131 MVT episodes
in 58 patients and 147 PVT or VF episodes in 61 pa-
tients (Online Table 2). Twenty-two (2.2%) patients
had >1 MVT treated episode over the average 3.1-year
follow-up. The 1- and 5-year Kaplan-Meier rates of
appropriate shock were 5.8% and 13.5% (MVT 3.8%
and 7.4%; PVT or VF 3.0% and 8.4%), respectively.
Differences in time to therapy were identiﬁed
between conversion testing and real-life VT or VF
episodes. The mean time to therapy was 15.1  3.5 s
for induced versus 18.4  4.3 s for spontaneous
episodes (p < 0.001). The time to therapy for MVT
episodes was 17.4  3.8 s, and 19.5  4.9 s for PVT or
VF episodes.Demographics of patients by type of appropriate
therapy, as well as univariate predictors of appropriate
therapy, are shown in Online Tables 1 and 3. In multi-
variate modeling for PVT or VF, a single MVT, or mul-
tiple MVT, secondary prevention patients were at the
highest risk of receiving appropriate therapy. Patients
with a prior cardiac arrest were at the highest risk for
both PVT or VF andMVT (Figure 4). Kidney disease was
an independent predictor of PVT or VF therapy,
whereas wider QRS interval and chronic obstructive
pulmonary disease at baseline were predictive of MVT,
and channelopathy patients were less likely to receive
therapy for MVT. In univariate modeling, ischemic
etiology at baseline was not associated with therapy
for PVT or VF (p ¼ 0.52) or MVT (p ¼ 0.20). A trend
toward increased incidence of multiple episodes of
MVT (p ¼ 0.090) failed to become signiﬁcant in
TABLE 2 Complications
Description Events Patients
% of
Patients
Infection requiring device removal 27 24 2.4
Erosion 17 17 1.7
Inappropriate shock: oversensing 12 11 1.1
Other procedural complications 13 10 1.0
Hematoma 9 9 0.9
Discomfort 8 8 0.8
Suboptimal electrode position 7 7 0.7
Electrode movement 7 7 0.7
Premature battery depletion 5 5 0.5
PG movement 6 5 0.5
Unable to convert during procedure 6 5 0.5
Incision/superﬁcial infection 5 5 0.5
Other technical complications 4 4 0.4
Suboptimal PG and electrode position 3 3 0.3
Inability to communicate with the device 3 3 0.3
Inappropriate shock: SVT above
discrimination zone (normal device
function)
2 2 0.2
Suboptimal pulse generator position 1 1 0.1
Total 135 115 11.7
PG ¼ pulse generator; SVT ¼ supraventricular tachycardia.
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836multivariate modeling (p ¼ 0.15). AF and valve disease
were associated with multiple MVT therapies. Pro-
gramming zones at implantation were included in all
multivariate models, and were not signiﬁcant factors
for appropriate or inappropriate shocks.
In discrete nonstorm VT or VF episodes, 88.5%
were converted on the ﬁrst shock and 97.4% (187 of
192 episodes) within 5 shocks available, whereas all
patients survived their arrhythmic events. First shock
conversion effectiveness was 90.5% for appropriately
treated discrete episodes of MVT and 86.6% for PVT
or VF. In 2 patients, VT termination occurred after the
ﬁfth shock, but was not documented in the time
frame of electrogram recording. In another 2 patients,
the device prematurely declared the episode ended
and immediately reinitiated a new episode, with VF
successfully terminated after additional shocks. One
patient undergoing a myectomy procedure received
multiple S-ICD and external shocks during the pro-
cedure. The subject was successfully deﬁbrillated
with an external deﬁbrillator during S-ICD
redetection.
Storm events (86 episodes in 13 VT or VF storm
events) were successfully converted in 12 events. One
patient with Loefﬂer’s syndrome experienced a storm
event that was not converted, as reported in a prior
publication (4). There have been no reports of other
deaths related to failed VT or VF conversion in the
rest of the full cohort.SURVIVAL. During the 3.1-year follow-up, 48 (4.8%)
patient deaths were reported (29 among prospective
enrollments and 19 in retrospective enrollments), of
which the primary cause was noncardiac in 21 pa-
tients, cardiac in 21, and unknown in 6. Of the cardiac
deaths, 1 was arrhythmic, as reported previously (4).
Other cardiac deaths were related to pump failure
(14 deaths), ischemic events (2 deaths), or other
cardiac causes (4 deaths). Forty-seven (98%) deaths
occurred outside the perioperative window of
30 days. No deaths were associated with the S-ICD
system procedure.
DISCUSSION
The present data provide important insights into the
midterm performance of the S-ICD in the most
comprehensively evaluated S-ICD cohort reported to
date (Central Illustration). Compared with the pre-
liminary EFFORTLESS registry publication by Lam-
biase et al. (4) >400 new patients were enrolled and
are reported on in this analysis. Analysis of the
retrospectively and prospectively enrolled cohorts
showed consistency in outcomes. The larger database
demonstrates consistent outcomes for efﬁcacy and
safety, in terms of successful conversion of both
induced and spontaneous clinical ventricular ar-
rhythmias, and the nature of inappropriate therapies.
It also provides insights into the factors that deter-
mine the likelihood of MVT versus PVT or VF therapy
in this S-ICD patient population, with implications for
TV-ICD versus S-ICD device prescription.
COMPLICATIONS. The rate of complications directly
caused by the S-ICD system, as well as the rate of all
S-ICD system- and procedure-related complications,
was low, and mirrored the IDE S-ICD rates, conﬁrming
the predictable and consistent safety of this ﬁrst-
generation device across geographies and patient
populations. The most common reason for interven-
tion was infection, whereas serious bloodstream
infection continued to be absent in the EFFORTLESS
registry population, as seen in earlier reports (5).
Complication rates improved as experience grew with
the S-ICD system, consistent with previous analyses
(5,7). The consistent results by indication and patient
demographics are also encouraging in this respect, as
no patient subgroup stands out for an elevated risk of
complications.
In comparison with TV-ICD complication rates, the
S-ICD rates are similar, although differences in de-
mographics, complication deﬁnitions, and follow-up
time make comparisons across studies challenging
(8). In 2 studies comparing matched S-ICD and TV-ICD
TABLE 3 Acute Conversion Testing
Final Conversion Result
(n ¼ 861)
Without
Repositioning
% of
Total
With
Repositioning
% of
Total Overall
% of
Total
Success #65 J 777 90.2 12 1.4 789 91.6
Success >65 J 36 4.2 2 0.2 38 4.4
Success at unknown energy 29 3.4 1 0.1 30 3.5
Summary of successful conversion 842 97.8 15 1.7 857 99.5
Failed conversion testing 2 0.2 2 0.2 4 0.5
FIGURE 3 Univariate Analysis of Complication Risk
1.10 (1.03 - 1.18)
Fewer Complications More Complications
Hazard Ratio (95% CI)
1.66 (1.07 - 2.58)
1.92 (1.06 - 3.50)
2.09 (0.97 - 4.49)
1.03 (1.00 - 1.06)
0.66 (0.42 - 1.03)
1.51 (0.95 - 2.41)
1.48 (0.90 - 2.42)
1.53 (0.88 - 2.68)
0.96 (0.91 - 1.02)
0.81 (0.56 - 1.18)
1.03 (0.97 - 1.09)
0.78 (0.41 - 1.50)
1.18 (0.76 - 1.81)
0.82 (0.47 - 1.43)
0.74 (0.27 - 2.01)
0.88 (0.57 - 1.36)
0.90 (0.60 - 1.34)
0.92 (0.60 - 1.39)
1.14 (0.60 - 2.19)
0.87 (0.41 - 1.87)
0.86 (0.35 - 2.12)
0.96 (0.60 - 1.54)
0.97 (0.64 - 1.46)
1.04 (0.63 - 1.72)
0.97 (0.49 - 1.92)
0.125 0.25 0.5 1 2 4 8
0.58 (0.14 - 2.35)
QRS (per 10 ms)
Non-Ischemic
Valve Surgery
Arrhythmogenic Right Ventricular Dysplasia
Body Mass Index (per 1 kg/m^2)
Myocardial Infarction
Previous Defibrillator
Valve Disease
Dilated Cardiomyopathy
Age (per 5 years)
Primary Prevention
Ejection Fraction (per 5 units)
Pacemaker
Diabetes
Channelopathy
Hypertrophic Cardiomyopathy
Chronic Obstructive Pulmonary Disease
Congestive Heart Failure
Male
Hypertension
Kidney Disease
Genetic Disease
Stroke
Syncope
Cardiac Arrest
Atrial Fibrillation
Coronary Artery Bypass Graft
Characteristic
0.004
P value
0.023
0.032
0.059
0.065
0.069
0.081
0.120
0.136
0.173
0.280
0.356
0.456
0.461
0.473
0.553
0.563
0.593
0.676
0.689
0.720
0.748
0.856
0.875
0.881
0.937
0.447
The complication risk is compared between patients with the characteristic present and those with the characteristic absent, or for each unit increase, as described
in Table 1.
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837patients, complication rates were equivalent, with
higher rates of lead complications in the TV-ICD pa-
tients and more nonlead complications, such as
erosion, in the S-ICD patients (9,10).
APPROPRIATE THERAPY. The study exclusion
criteria mimic the device contraindications by
excluding patients with a history of recurring VT who
could beneﬁt from ATP. This is likely to skew the
demographics of this study in comparison with TV-
ICD studies. The average age is younger than in TV-
ICD studies, with a higher proportion of inherited
diseases than would be expected in a TV-ICD study.
It is not surprising that secondary prevention pa-
tients and patients with prior cardiac arrest were
more likely to receive appropriate therapy, whetherfor PVT or VF or MVT. Patients with ion channelop-
athy were less likely to receive therapy for MVT.
Renal disease was a signiﬁcant predictor of therapy
for PVT or VF, which was not seen in the IDE trial that
excluded patients with renal disease. Serum creatinine
FIGURE 4 Multivariate Analysis of the Risk of Appropriate Therapy
Lower Rate
of Therapy
Higher Rate
of TherapyHazard Ratio (95% CI)
2.65 (1.72 - 4.10)
2.10 (1.18 - 3.75)
1.04 (1.01 - 1.07)
3.43 (2.06 - 5.70)
2.35 (1.19 - 4.64)
2.48 (1.04 - 5.88)
2.03 (1.17 - 3.53)
0.32 (0.11- 0.89)
2.28 (0.90 - 5.82)
2.22 (0.84 - 5.88)
0.0625 0.250.125 0.5 1 2 4 8
1.13 (1.04 - 1.23)
Any Appropriate Therapy
Type of Appropriate Therapy
Secondary Prevention
Kidney Disease
Body Mass Index (per 1 kg/m^2)
Appropriate Therapy for PVT/VF
Cardiac Arrest
Kidney Disease
Appropriate Therapy for MVT
Chronic Obstructive Pulmonary Disease
Cardiac Arrest
QRS (per 10 ms increase)
Channelopathy
>1 treated MVT
Atrial Fibrillation
Valve Disease
Characteristic
P value
<0.001
0.012
0.017
0.000
0.014
0.040
0.012
0.028
0.083
0.109
0.005
The ﬁgure shows signiﬁcant prognostic factors using Cox proportional hazards models for the risk of receiving appropriate therapy. Separate models were constructed
and are shown for any type of appropriate therapy received, and by type of rhythm receiving appropriate therapy: polymorphic ventricular tachycardia (PVT) or
ventricular ﬁbrillation (VF), monomorphic ventricular tachycardia (MVT), or multiple treated MVTs. CI ¼ conﬁdence interval.
Boersma et al. J A C C V O L . 7 0 , N O . 7 , 2 0 1 7
The EFFORTLESS S-ICD Study Midterm Results A U G U S T 1 5 , 2 0 1 7 : 8 3 0 – 4 1
838and renal dysfunction has been seen as an indepen-
dent predictor of the time to ﬁrst appropriate shock
and sudden cardiac death in several TV-ICD studies
(11–13). Patients with ischemic cardiomyopathy were
not signiﬁcantly more likely to receive appropriate
therapy. This is consistent with MADIT-RIT (Multi-
center Automatic Deﬁbrillator Implantation Trial–
Reduce Inappropriate Therapy) and SCD-HeFT
(Sudden Cardiac Death in Heart Failure Trial) trial
results in primary prevention patients (14,15).
A wider baseline QRS interval was an independent
predictor of any appropriate therapy and treated
MVT. Baseline AF was also associated with multiple
treated MVT episodes. The results are consistent with
SCD-HeFT trial modeling of arrhythmia risk (14),
as both factors were found to be predictive, as was
left bundle branch block in MADIT-II (Multicenter
Automatic Deﬁbrillator Implantation Trial II) trial
(16). AF may either track with structural heart disease
in its own right or promote ventricular arrhythmias
through continuous cycle-length changes in the
ventricle, which induce changes in ventricular
refractoriness, leading to ventricular arrhythmia
initiation. This reﬂects the ﬁnding of the PROFIT
(Prospective Analysis of Risk Factor for AppropriateICD Therapy) study, where patients with at least
2 risk factors (ejection fraction <40%, AF, QRS
width $150 ms) had a 2-year 100% risk of VT or VF
occurrence, compared with 19.3% and a 2-year risk of
25% with no or 1 risk factor (17). Furthermore, the
JEWEL AF study showed that atrial tachyarrhythmias
increase the risk of ventricular arrhythmias in
patients with ICDs (18).
THE RELEVANCE OF MVT AND LACK OF ATP. This
long-term follow-up of the entire EFFORTLESS reg-
istry cohort conﬁrms the ﬁndings in the pooled IDE-
EFFORTLESS registry analysis that the incidence of
treated MVT in S-ICD recipients (5.8% in 3.1 years) is
low; 36 (3.6%) patients with a single MVT episode and
22 (2.2%) patients with >1 MVT episode all success-
fully converted by 1 shock in the clear majority of
cases. Five (0.5%) patients had the device removed
for conceived need for ATP. Combining the cohorts
with recurrent MVT and exchange for ATP would
lead to an annualized rate of 0.9% of patients who
might have beneﬁtted from ATP. Extrapolating the
PainFREE RX II (Pacing Fast Ventricular Tachycardia
Reduces Shock Therapies) trial ATP efﬁcacy of 42%
for VT termination to this would yield 0.4% of pa-
tients annually that might have avoided recurrent
CENTRAL ILLUSTRATION Outcomes After S-ICD Implantation: 1-Year EFFORTLESS Registry
100%95%90%85%80%
97.4%
98.9%
98.5%
98.0%Freedom from S-ICD Complication (1 Year)
Freedom from Inappropriate Shock for
AF/SVT (1 Year)
No Change to TV-ICD
Shock Efficacy
Boersma, L. et al. J Am Coll Cardiol. 2017;70(7):830–41.
Chart demonstrates freedom from subcutaneous implantable cardioverter-deﬁbrillator (S-ICD) complication; freedom from inappropriate
shock for atrial ﬁbrillation (AF) or supraventricular tachycardia (SVT); no change to transvenous implantable cardioverter-deﬁbrillator
(TV-ICD); and shock efﬁcacy at 1 year. EFFORTLESS S-ICD ¼ Evaluation oF FactORs ImpacTing CLinical Outcome and Cost EffectiveneSS of the
S-ICD.
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like PRAETORIAN (A PRospective, rAndomizEd
Comparison of subcuTaneOous and tRansvenous
ImplANtable Cardioverter Deﬁbrillator Therapy) trial,
directly comparing TV-ICD to S-ICD, may provide
more data to decide if the beneﬁt of ATP in the few,
outweighs the disadvantages in the many (19). Such
data will assist implanters to make an individual
patient-based choice of the type of deﬁbrillator.
High-rate programming to evaluate ATP need has
been evaluated in TV-ICD studies. Clementy et al.
(20) showed that programming shock-only therapy
above >220 beats/min was not associated with
adverse consequences, with 11.2% of patients
receiving appropriate shocks and 6.6% inappro-
priate shocks over 3.3 years. Ventricular arrhyth-
mias, sustained or not, were recorded in the
monitoring zone (170 to 220 beats/min) in 11.8% of
patients, of which only a few were symptomatic
(1.9%), with no lethal consequences. In the
EFFORTLESS registry cohort, the actual appropriate
shock rate of 10.5% of patients (3.4%/annum)
appears to be in line with TV-ICD studies with
contemporary programming.INAPPROPRIATE SHOCKS AND THE EFFECTS OF
PROGRESSIVE CHANGES IN PROGRAMMING. The
pre-speciﬁed primary endpoint of inappropriate
therapy for AF or SVT was as low as 1.5% at 1 year in
the EFFORTLESS registry. The overall inappropriate
shock rate of 8.1% at 1 year appears to be similar to
the overall rate in historical TV-ICD studies of 7% to
10% in the ﬁrst year, rising to 18% by the ﬁfth year
(21–24). Although inappropriate shocks in MADIT-II
trial of 10% were primarily due AF or SVT episodes
(80%), T-wave oversensing was the main cause for
the S-ICD. The second-generation S-ICD detection
algorithms, available in only 7.6% of EFFORTLESS
registry patients, may reduce inappropriate shocks
due to cardiac oversensing by 30% to 40% (25).
Modeling studies of the latest EMBLEM S-ICD (Boston
Scientiﬁc, Inc., Minneapolis–St. Paul, Minnesota)
algorithms using episodes from the EFFORTLESS
registry showed a potential all-cause inappropriate
shock incidence as low as 3.8% (70% to 80% reduc-
tion) (26).
The S-ICD inappropriate shock rate is higher than
reported in the latest TV-ICD studies with more strict
and controlled programming. The differences with
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: S-ICD therapy is associated
with a low incidence of device-related complications
and low rate of inappropriate discharge for atrial
tachyarrhythmias at 1 year, with 98% efﬁcacy for
ventricular arrhythmias during 3-year follow-up.
TRANSLATIONAL OUTLOOK: Advances in
hardware and software technology and developments
in leadless pacing modalities could expand the
application for these less invasive therapeutic devices
to a wider range of patients.
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840the latest TV-ICD shock rates may be caused by a
difference in patient demographics. In the MADIT-
RIT trial, each decade of age was associated with
34% reduction in the risk of inappropriate shock
(27). In addition, a recent meta-analysis found TV-
ICD inappropriate shock rates of 13% to 22% in
patients with hypertrophic cardiomyopathy, long
QT syndrome, arrhythmogenic right ventricular
cardiomyopathy, and Brugada syndrome (28). This
demographic makes up nearly one-third of the
EFFORTLESS registry cohort. In a matched compari-
son of S-ICD to TV-ICD, Brouwer et al. (9) observed no
signiﬁcant difference in rates of inappropriate shocks
between S-ICD and TV-ICD patients over 5 years, with
the S-ICD 1-year rate of inappropriate shocks of 8.4%
being similar to the rate seen in the EFFORTLESS
registry.
Programming was also uncontrolled in the
EFFORTLESS registry. During the course of the study,
dual-zone programming at implantation increased
from 57% in 2009 to 2010, to 85% in 2011, and >90%
in 2012 to 2014, whereas average rate cutoffs at im-
plantation were raised from 208 beats/min to 224
beats/min with single-zone programming, and from
190/227 beats/min to 199/233 beats/min with dual-
zone programming (Online Figure 1). In parallel to
this change in implantation practice, the current
longer-term multivariate analysis no longer identiﬁed
dual-zone programming as lowering the rate of
inappropriate therapy, whereas single-zone pro-
gramming inappropriate therapy rates were lower
than in previous studies (5). Alternative explanations
could be reprogramming after implantation, the types
of patients programmed to a single zone, or that an
analysis artifact due to a low number of patients
programmed to a single zone could have inﬂuenced
these ﬁndings. In view of the collective data of
several S-ICD studies, dual-zone programming should
remain the standard for all patients.
LESSONS LEARNED FROM CONVERSION TESTING.
As S-ICD technology is still novel, conversion testing
during implantation is still recommended to ensure
optimal sensing of induced VF and effective deﬁbril-
lation (29). In the EFFORTLESS registry, there were
no cases of VF under-detection preventing shock
delivery, and failed acute conversion testing occurred
in only a limited number of patients (<1%). Reposi-
tioning of the electrode or generator to encompass
the heart may be needed to achieve successful con-
version. In patients with a high body mass index, both
the electrode and the generator must be positioned
under the fat, in direct contact with the fascia, to
ensure optimal shock impedances.STUDY LIMITATIONS. The EFFORTLESS registry
follow-up is ongoing, following patients to 5 years,
and new events may be reported. A survival bias may
be present in study patients who enrolled retrospec-
tively post-implantation and had survived to the
point of enrollment. The patient group selected and
studied in EFFORTLESS is different from that in
the classic TV-ICD trials, which hampers direct
comparison.
CONCLUSIONS
This analysis of the full EFFORTLESS cohort over
the ﬁrst year post-implantation demonstrates that
the S-ICD remains safe and effective in the
treatment of lethal ventricular arrhythmias, with a
low incidence of device upgrade for bradycardia,
cardiac resynchronization therapy pacing, or ATP,
and a low rate of implant complications. Current
patient selection and device programming are
efﬁcacious, and avoid the unnecessary use of
transvenous leads with their attendant complica-
tions. This cohort forms a key dataset in
evaluating clinical outcomes with this new
technology.
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